Mohammad Hirmand Acquires Shares of Whitehawk Therapeutics
Whitehawk Therapeutics sees insider buying activity as Mohammad Hirmand acquires 38,040 shares.
Key Points
- On June 12, 2026, Mohammad Hirmand bought 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK).
- Whitehawk Therapeutics has a market cap of approximately $202.8 million and trades near $4.16 per share.
- Analysts have set a mean target price of $6.50 for Whitehawk Therapeutics with a 'buy' recommendation.
On June 12, 2026, Mohammad Hirmand bought 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK). This insider activity comes as the company's stock trades around $4.16 per share.
Other Institutional Activity in Whitehawk Therapeutics
Several funds hold significant positions in Whitehawk Therapeutics. QVT Financial LP holds 4,615,709 shares valued at approximately $15.9 million. Orbimed Advisors LLC has 4,166,000 shares worth about $14.4 million. Suvretta Capital Management, LLC owns 3,700,000 shares valued at $12.8 million. Acuta Capital Partners, LLC's stake includes 3,410,402 shares worth roughly $11.8 million, while Avoro Capital Advisors LLC holds 2,849,402 shares valued at $9.8 million.
Whitehawk Therapeutics Stock Snapshot
Shares of Whitehawk Therapeutics (NasdaqCM: WHWK) traded near $4.16. The company has a market cap of approximately $202.8 million. It has no meaningful P/E ratio due to its lack of profitability, but its forward P/E is -3.35. The stock's beta is 0.769, indicating lower volatility relative to the market. It has a 52-week range between $1.57 and $5.50, with a 50-day moving average of $4.15 and a 200-day moving average of $2.98. The company maintains a robust current ratio of 11.36 and a quick ratio of 11.13.
Recent Earnings
Whitehawk Therapeutics is expected to report its next earnings on August 6, 2026. The company reported an EPS of -$2.49, with no net margin. Its return on equity stands at -68.54%.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, several insiders, including Castelein Caley, Desai Neil, Reeve Emma, Maroun Richard, Zhao Baiteng, and Aghazadeh Behzad, each purchased 38,040 shares of Whitehawk Therapeutics. These transactions were not made under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On April 16, 2026, Citizens initiated coverage of Whitehawk Therapeutics with a 'buy' rating and set a price target of $8.00. Earlier, on December 22, 2025, Jones Trading also initiated coverage with a 'buy' rating and a $7.00 target price. The consensus among analysts is a 'buy' recommendation with a mean target price of $6.50, based on four analyst opinions.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc. is a biotechnology company based in Morristown, New Jersey. Led by CEO Dr. David J. Lennon, the company focuses on developing oncology therapeutics. It offers a portfolio of next-generation antibody drug conjugates aimed at improving cancer treatment. The company, which was formerly known as Aadi Bioscience, Inc., was incorporated in 2007 and employs 29 people.
Bottom Line
Insider buying activity at Whitehawk Therapeutics suggests confidence in the company's future. With a market cap of about $202.8 million and a stock price near $4.16, investors are keeping a close eye on its developments. Analyst ratings also reflect optimism, with a consensus 'buy' recommendation and a target price of $6.50. Keep in mind that insider and institutional activities are historical and may not reflect current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.